HC Wainwright Raises Virios Therapeutics (NASDAQ:VIRI) Price Target to $5.00

Virios Therapeutics (NASDAQ:VIRI) had its price target boosted by HC Wainwright from $0.20 to $5.00 in a research note issued to investors on Wednesday, Benzinga reports. They currently have a neutral rating on the stock.

Separately, Maxim Group assumed coverage on Virios Therapeutics in a report on Thursday, June 20th. They set a buy rating and a $1.00 price target on the stock.

Virios Therapeutics Stock Up 32.0 %

NASDAQ:VIRI opened at $4.12 on Wednesday. The business’s 50-day simple moving average is $0.38 and its two-hundred day simple moving average is $0.34. The stock has a market cap of $79.34 million, a PE ratio of -15.26 and a beta of 1.58. Virios Therapeutics has a 52 week low of $0.13 and a 52 week high of $1.04.

Virios Therapeutics (NASDAQ:VIRI) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.05) EPS for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.02. During the same period in the prior year, the firm earned ($0.08) EPS. Sell-side analysts anticipate that Virios Therapeutics will post -0.22 earnings per share for the current fiscal year.

About Virios Therapeutics

Virios Therapeutics, Inc, a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia.